Artificial intelligence might seem more the preserve of computer nerds and tech giants than pharma companies. But according to Boehringer Ingelheim's global chief data scientist, Philipp Diesinger, "the entire industry is looking at data science and AI". This increased focus on data could drastically change the way drugs are developed and paid for. For example, AI will be vital if outcomes-based healthcare is to be successfully implemented, pointed out Philips' chief innovation & strategy officer, Jeroen Tas, who also stressed that AI really signaled a new way of handling data. He described AI as "the way you interpret data.
In an effort to provide our most diverse pharmaceutical and medical device executive mix to date, this year's venue provides a centralized platform that is close to numerous UK pharma headquarters as well as Heathrow Airport. This will also allow for easy access to UK pharmaceuticals and medical device organizations and facilitate expedited travel time for European and US counterparts.
Insilico Medicine is pleased to announce that it has entered into a research collaboration with Boehringer Ingelheim to utilize Insilico's generative machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying potential therapeutic targets implicated in a variety of diseases. "Insilico Medicine is very impressed with the Research Beyond Borders group at Boehringer Ingelheim capabilities in the search of potential drug targets. In this collaboration, Insilico will provide additional AI capabilities to discover novel targets for a variety of diseases to benefit the patients worldwide. We are very happy to partner with such an advanced group," said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine. "We believe that Insilico's exclusive Pandomics platform will provide huge boost to our ability to explore and identify drug targets. We look forward to using AI to significantly improve the drug discovery process and contribute to human health," said from Dr. Weiyi Zhang, Head of External Innovation Hub, Boehringer Ingelheim Greater China.
Digital technologies can transform how companies approach clinical development by incorporating valuable insights from multiple sources of data, radically improving the patient experience, enhancing clinical trial productivity, and increasing the amount and quality of data collected in trials. But where is the industry in adopting these transformative technologies? We interviewed 43 leaders across the clinical development ecosystem to understand the current level of adoption of digital technologies and how it can be accelerated. We found that the industry has been slow to digitize its clinical development processes, and that digital adoption varies widely. Even the most advanced organizations are simply piloting several technologies in different areas of clinical development, focusing on piecemeal solutions or new tools to support the existing process. Our research and client experience suggest that digital transformation is a complex, resource-intensive, and lengthy undertaking. But the rewards can be significant: Early adopters can benefit from better access to and engagement with patients, deeper insights, and faster cycle times for products in development. Many in our study expressed a desire to be fast followers, but given the complexity of operationalizing a digital strategy, the reality is that undue delay could put organizations at a competitive disadvantage. At the same time, our research also indicates that biopharma companies and contract research organizations (CROs) will need to overcome several challenges to realize the potential of digital in clinical development: immature data infrastructure and analytics, regulatory considerations, and internal organizational and cultural barriers. Biopharma companies should consider building updated data infrastructure and governance, engaging early with regulators to discuss new technologies, and developing a measured approach to evaluating and implementing technologies within their organizations. CROs can enable this change by advancing interoperable digital platforms and vetting promising technology applications. Cross-industry consortia could help advance the industry as a whole by offering a forum to share early successes and supporting the development of standards. The time to act is now.
It's that time when we start to look ahead to what next year holds for the life science sector...Lu Rahman outlines 2020s big medtech players A decade ago the healthcare advances create by AI would have seemed the stuff of dreams. But back in 2018 Theresa May announced plans to use artificial intelligence and data to transform the way certain diseases like cancer. The technology is moving at a pace – this year we heard that a team led by the University of Surrey had filed the first ever patent for inventions autonomously created by AI without a human inventor. Professor Ryan Abbott explained the implications this had for the life science sector: "These filings are important to any area of research and development as well as any area that relies on patents. Patents are more important in the life sciences than in many other areas, particularly for drug discovery. These tasks can be the foundation for patent filings. "As AI is becoming increasingly sophisticated, it is likely to play an increasing role in R&D including in the life sciences.